a-defa14a_20200318.htm

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

	☐	Preliminary Proxy Statement

	☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

	☐	Definitive Proxy Statement

	☒	Definitive Additional Materials

	☐	Soliciting Material Pursuant to §240.14a-12

Payment of Filing Fee (Check the appropriate box):

	☒	No fee required.

	☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

		(1)	Title of each class of securities to which transaction applies:
		(2)	Aggregate number of securities to which transaction applies:
		(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
		(4)	Proposed maximum aggregate value of transaction:
		(5)	Total fee paid:

	☐	Fee paid previously with preliminary materials.

	☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

		(1)	Amount Previously Paid:
		(2)	Form, Schedule or Registration Statement No.:
		(3)	Filing Party:
		(4)	Date Filed:

This proxy statement supplement, dated March 4, 2020 (which we refer to as the “Supplement”), supplements the definitive proxy statement (which we refer to as the “Proxy Statement”) of Agilent Technologies, Inc. filed with the Securities and Exchange Commission on February 6, 2020 relating to the annual meeting of stockholders to be held on Wednesday, March 18, 2020 at 8:00 a.m., Pacific Time, at our Corporate Headquarters, 5301 Stevens Creek Boulevard, Building No. 5, Santa Clara, California 95051.

The purpose of this Supplement is to provide additional information with respect to George A. Scangos, Ph.D., a director nominee. We recently learned that Dr. Scangos will retire and will not be seeking re-election to the board of Exelixis, Inc., one of the other public companies at which he is currently a director. Therefore, on or about May 20, 2020, Dr. Scangos will no longer be a director of Exelixis, Inc. and as a result will serve on only two public company boards of directors, Agilent Technologies, Inc. and Vir Biotechnology, Inc., where he is CEO.

Except as specifically amended or supplemented by the information contained in this Supplement, all information set forth in the Proxy Statement and proxy card remain accurate and should be considered in voting your shares.